Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Public ClinicalTrials.gov record NCT01269346. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter phase 2 study designed to evaluate the safety and efficacy of eribulin mesylate in combination with trastuzumab as first line treatment in female subjects with locally recurrent or metastatic human epidermal growth factor receptor (HER2) positive breast cancer.
Study identification
- NCT ID
- NCT01269346
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2010 (Type not available)
- Primary completion
- Mar 2013 (Actual)
- Completion
- May 2016 (Actual)
- Last update posted
- Jun 22, 2023
2010 – 2016
United States locations
- U.S. sites
- 26
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado | Denver | Colorado | 80204 | — |
| Florida Cancer Care | Davie | Florida | 33328 | — |
| Florida Oncology Associates | Jacksonville | Florida | 32256 | — |
| Ocala Oncology Center | Ocala | Florida | 34471 | — |
| Peachtree Hematology Oncology Associates, PC | Atlanta | Georgia | 30309 | — |
| Northwest Georgia Oncology Centers, P.C. | Marietta | Georgia | 30060 | — |
| Montgomery Cancer Center | Mount Sterling | Kentucky | 40353 | — |
| Jackson Oncology Associates, PLLC | Jackson | Mississippi | 39202 | — |
| Heartland Regional Medical Center | Saint Joseph | Missouri | 64507 | — |
| Weill Cornell Breast Clinic | New York | New York | 10065 | — |
| Raleigh Hematology Associates | Raleigh | North Carolina | 27607 | — |
| Cancer Care of the Cascades | Bend | Oregon | 97701 | — |
| Medical Oncology Associates of Wyoming Valley, P.C. | Kingston | Pennsylvania | 18704 | — |
| Charleston Hematology/Oncology | Charleston | South Carolina | 29403 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29403 | — |
| C. Michael Jones, MD | Germantown | Tennessee | 38138 | — |
| Texas Oncology - Beaumont Marnie McFaddin Ward Cancer Center | Beaumont | Texas | 77702-1449 | — |
| Texas Oncology - Medical City Dallas | Dallas | Texas | 75201 | — |
| Texas Oncology - El Paso Cancer Treatment Center Grandview | El Paso | Texas | 79902 | — |
| Texas Oncology - Memorial City | Houston | Texas | 77024 | — |
| Texas Oncology - McAllen South Second Street | McAllen | Texas | 78503 | — |
| Cancer Care Centers of South Texas | San Antonio | Texas | 78217 | — |
| Texas Oncology - Sherman | Sherman | Texas | 75090 | — |
| Texas Oncology - Sugar Land | Sugar Land | Texas | 77479 | — |
| Pensisula Cancer Institute | Newport News | Virginia | 23601 | — |
| Columbia Basin Hematology and Oncology | Kennewick | Washington | 99336 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01269346, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 22, 2023 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01269346 live on ClinicalTrials.gov.